MaxGun Sublingual Spray represents a significant advancement in the delivery of fast-acting analgesic medication for patients requiring immediate and effective pain control. Utilizing a sublingual administration route, this formulation ensures rapid systemic absorption, bypassing first-pass metabolism to provide quicker onset of action compared to traditional oral analgesics. Designed for both clinical and at-home use under medical supervision, it offers a reliable option for managing moderate to severe acute pain episodes with precision and convenience.

Features

• Contains a precisely measured dose of active analgesic compound per spray
• Sublingual delivery system for enhanced bioavailability and rapid onset
• Portable, discreet design with child-resistant safety cap
• Calibrated actuator for consistent dosing accuracy
• Tamper-evident packaging ensuring product integrity
• Shelf-stable formulation requiring no refrigeration
• Ethanol-free and sugar-free excipient base
• Manufactured in a cGMP-compliant facility

Benefits

• Achieves therapeutic plasma concentrations within minutes for immediate pain relief
• Offers predictable pharmacokinetics, allowing for tailored dosing regimens
• Eliminates the need for swallowing, ideal for patients with dysphagia or nausea
• Provides precise dosing control, reducing the risk of under- or over-medication
• Enables discreet administration in various settings without water or additional devices
• Reduces gastrointestinal irritation associated with oral analgesic formulations

Common use

MaxGun Sublingual Spray is indicated for the management of breakthrough pain in adults already receiving and tolerant to opioid therapy for persistent cancer pain. It may also be prescribed off-label for other acute pain conditions where rapid analgesia is required, such as postoperative pain, trauma-related pain, or severe musculoskeletal pain episodes, following comprehensive clinical assessment and risk-benefit evaluation by a qualified healthcare provider.

Dosage and direction

Administer exactly as prescribed by your physician. The initial dose is typically one spray (100 mcg) sublingually, directed under the tongue. Do not swallow immediately; allow the medication to absorb through the mucosal membrane for 60–90 seconds. If pain persists after 30 minutes, a second spray may be administered as directed. Do not exceed two doses per episode. Wait at least 4 hours before treating another pain episode. The maximum daily dosage should not exceed 4 sprays (400 mcg) unless specifically instructed by your healthcare provider. Regularly reassess the need for continued opioid therapy.

Precautions

Use with caution in patients with respiratory depression, chronic obstructive pulmonary disease, or cor pulmonale. Monitor for signs of hypotension in patients with hypovolemia, cardiovascular disease, or on concomitant vasodilator therapy. Avoid use in patients with head injury or increased intracranial pressure due to risk of obscuring neurological signs. May cause severe drowsiness; refrain from driving or operating machinery until effects are known. Not recommended during pregnancy unless potential benefits justify potential risks to the fetus. Keep out of reach of children and pets.

Contraindications

Hypersensitivity to the active compound or any excipients. Significant respiratory depression in unmonitored settings or absence of resuscitative equipment. Acute or severe bronchial asthma. Known or suspected gastrointestinal obstruction, including paralytic ileus. Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such treatment.

Possible side effect

Common (≥1%): nausea, dizziness, somnolence, vomiting, fatigue. Less common (<1%): headache, dry mouth, hyperhidrosis, pruritus, abdominal pain. Rare but serious: respiratory depression, apnea, hypotension, bronchospasm, anaphylaxis. Report any persistent or severe adverse reactions to your healthcare provider immediately. Long-term use may lead to physical dependence and tolerance.

Drug interaction

Potentially serious interactions with: benzodiazepines, other CNS depressants (increased risk of respiratory depression); serotonergic drugs (risk of serotonin syndrome); mixed agonist/antagonist analgesics (may precipitate withdrawal); CYP3A4 inhibitors (increased plasma levels); anticholinergic drugs (increased risk of urinary retention). Always inform your prescriber of all medications, including OTC products and herbal supplements.

Missed dose

As this medication is prescribed for as-needed pain relief, missed doses are not applicable. Do not administer extra spray to make up for a missed administration. Use only when experiencing breakthrough pain, adhering to the minimum effective dose and frequency as directed.

Overdose

Symptoms may include respiratory depression, extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death. In case of suspected overdose, seek emergency medical attention immediately. Naloxone may be administered as an antidote under medical supervision, though multiple doses may be required due to the prolonged duration of action. Provide supportive measures including airway management and assisted ventilation.

Storage

Store at controlled room temperature (20–25°C). Excursions permitted between 15–30°C. Protect from light and moisture. Do not freeze. Keep the bottle tightly closed and upright. Discard any unused medication 60 days after first opening, even if spray remains. Dispose of unused medication via drug take-back programs or according to local regulations.

Disclaimer

This product is available by prescription only. This information is not exhaustive and does not replace professional medical advice. Always follow the specific instructions provided by your healthcare provider. The prescriber should be familiar with the complete prescribing information and potential risks of opioid therapy.

Reviews

“Effective for rapid onset pain control in palliative care patients. The sublingual route is particularly beneficial for those with swallowing difficulties.” – Dr. Elena Rostova, MD, Pain Management Specialist
“Provides predictable analgesia with fewer GI side effects compared to oral formulations. Dosing requires careful patient education.” – Clinical Pharmacist, Oncology Unit
“Patients appreciate the convenience and speed of relief. Must be used with strict adherence to prescribing guidelines to minimize misuse potential.” – Pain Clinic Director